Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Company Overview

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102). Piclidenoson is being evaluated for the treatment of rheumatoid arthritis and psoriasis, with pivotal studies designed to demonstrate efficacy and safety in patients who have shown inadequate responses to existing therapies. Namodenoson is in clinical development for hepatocellular carcinoma and nonalcoholic steatohepatitis (NASH), conditions with limited treatment options and high unmet demand. Can-Fite’s pipeline also features earlier-stage programs aimed at expanding the application of its adenosine receptor technology across additional therapeutic areas.

Can-Fite conducts its clinical trials in multiple geographies, including North America, Europe and Israel, collaborating with leading research institutions and contract research organizations to ensure rigorous study design and execution. The company has entered into strategic partnerships and licensing agreements to facilitate development, regulatory filing and potential commercialization of its product candidates. These collaborations are intended to extend Can-Fite’s global reach and leverage external expertise to accelerate development timelines.

Under the leadership of Chief Executive Officer Pnina Fishman, Can-Fite has maintained a focused strategy on clinical advancement and regulatory engagement. The management team brings extensive experience in biopharmaceutical development, regulatory affairs and commercial strategy. Looking ahead, Can-Fite aims to complete late-stage trials for its lead candidates, pursue regulatory approvals, and explore additional indications for its adenosine receptor platform to deliver new treatment options for patients worldwide.

Key Stats

• Today's Range: $3.15 to $3.36
• 50-Day Range: $2.75 to $4.63
• 52-Week Range: $2.56 to $14.06
• Volume: 15,281 shs
• Average Volume: 1.12 million shs
• Market Capitalization: $2.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Moderate Buy

Can-Fite BioPharma Stock Analysis - MarketRank™

Can-Fite BioPharma scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Can-Fite BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Can-Fite BioPharma has a consensus price target of $44.00, representing about 1,272.4% upside from its current price of $3.21.

Amount of Analyst Coverage

Can-Fite BioPharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Can-Fite BioPharma is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Can-Fite BioPharma is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Can-Fite BioPharma has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CANF.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Can-Fite BioPharma does not currently pay a dividend.

Dividend Growth

Can-Fite BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for CANF on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.80% of the stock of Can-Fite BioPharma is held by insiders.

Percentage Held by Institutions

21.00% of the stock of Can-Fite BioPharma is held by institutions.

Company Calendar

• Last Earnings: 11/30/2021
• Today: 7/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:CANF
• CIK: 1536196
• Web: www.canfite.com
• Phone: 972-3-924-1114
• Fax: 972-3924-9378
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Can-Fite BioPharma: $44.00
• High Price Target: $80.00
• Low Price Target: $8.00
• Potential Upside/Downside: +1,296.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $405 thousand
• Price / Sales: 5.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 1.79

Miscellaneous

• Outstanding Shares: 655,000
• Free Float: N/A
• Market Cap: $2.06 million
• Optionable: Not Optionable
• Beta: 1.11